undamentalytics Newsletter
Sign in

Petmed Express Inc (PETS) stock

Add to watchlist

Add holding +

NASDAQ: PETS Nasdaq Health Care Services Next results ~November 10, 2026

C Fundamentals grade

Petmed Express Inc is a US-listed company in the health care services industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.0

Revenue-to-maturity cash-flow model

Base case. Range ~$1.0–$1.6 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Petmed Express Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds19 adding, 27 cuttingOf 11 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Petmed Express files

Where Petmed Express stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $169m, down 20.3% on a year earlier, a smaller fall than the 21.1% decline a quarter earlier. That puts it 32 of 34 for growth among the health care services companies we cover. Free-cash-flow margin fell to -16.4% from -2.2% a year earlier. The diluted share count is up 2.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.99 a share, against a share price of $1.19.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Petmed Express Inc's trailing-twelve-month revenue fell 20.3% year on year, with a free-cash-flow margin of -16.4%. Where it stands out: days sales outstanding of 4 days ranks 1 of 31 health care services companies we cover. Where it lags: revenue growth of -20.3% ranks 38 of 41 health care services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 483.7% while net income grew 33.7%: a 517pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Petmed Express Inc's latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 16 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 20.3% over the last 12 months.
  • Loss-making. Operating margin is -18.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -16.4% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 96% and a beta of 1.4 against the S&P 500.

Latest results: FY2027 Q1

Filed August 13, 2026
Earnings per share
-$0.28 against an average estimate of $0.12: missed by 333.3%
Revenue
$41m, down 19.9% on a year earlier
Share reaction
-9.0% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 10, 2026

Petmed Express' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.8%
  • 1 week+3.4%
  • 1 month-11.8%
  • This year-62.5%
  • 1 year-53.3%
  • 5 years-95.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$169M
Operating margin
-18.2%
Net margin
-17.3%
EPS (TTM, diluted)
$-1.38

Growth

Revenue growth
−20.3%
Change in growth rate
+0.8 pts
Share count change
+2.9%

Cash

Free cash flow (TTM)
-$27.8M
FCF margin
-16.4%
Stock pay % of revenue
0.6%

Earnings

Last results
August 13, 2026
Next results (est.)
November 16, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Leadership
  3. Leadership
  4. Results
  5. Leadership
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Petmed Express Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Petmed Express Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$1.0 ~$1.0–$1.6 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$3.7–$18 Left out: out of range vs price (0.17x)
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.0 ~$1.0–$1.6 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Petmed Express Inc with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$12.95$15.13$32.02$18.10$24.06$30.43$23.30$15.56$4.79$4.19$2.28$1.20
Market value$262m$308m$654m$371m$483m$612m$474m$317m$98m$86m$48m$25m
+ Net debt (− = net cash)−$38m−$59m−$78m−$101m−$104m−$119m−$111m−$104m−$55m−$55m−$21m−$13m
Enterprise value$225m$250m$576m$270m$379m$493m$363m$212m$42m$32m$26m$12m
Multiples
Price / sales 1.1x1.2x2.4x1.3x1.7x2.0x1.7x1.3x0.4x0.4x0.3x0.2x
Price / earnings 12.7x12.9x17.5x9.8x18.7x25.6x25.3x61.6x————
Price / free cash flow n/m8.4x17.8x8.3x13.2x16.3x28.3x14.0x————
EV / EBITDA 6.8x6.4x10.6x5.6x11.4x15.0x13.4x22.1x—5.7x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

54 /100

Moderate moat

How hard Petmed Express's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 13.0% of total assets over 10 years.

  • Pricing power 11 / 20

    Gross margin has been a median 30.1%, moving by 2.2 percentage points (standard deviation) across 10 years.

  • Durability 2 / 20

    Operating margin has been a median 10.2%; its worst year was -18.9%.

  • Cash conversion 11 / 20

    Free cash flow was positive in 7 of 10 years, at a median 8.3% of revenue.

  • Discipline 15 / 20

    The diluted share count rose 4.9% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (59 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.50 +82% $149m −17%
Next −$0.35 +30% $152m +2%

Next year's EPS estimate has moved −488.9% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −814.3% on 90 days ago. In the last 30 days, 0 analysts raised Petmed Express Inc's forecast and 1 cut it.

Consensus EPS forecast Petmed Express Inc, last 90 days
−$0.60 −$0.40 −$0.20 $0.00 $0.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.07 Current fiscal year, 60 days ago: $0.07 Current fiscal year, 30 days ago: $0.07 Current fiscal year, 7 days ago: $0.07 Current fiscal year, Now: −$0.50 −$0.50 Next fiscal year, 90 days ago: $0.09 Next fiscal year, 60 days ago: $0.09 Next fiscal year, 30 days ago: $0.09 Next fiscal year, 7 days ago: $0.09 Next fiscal year, Now: −$0.35 −$0.35

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.07$0.09
60 days ago $0.07$0.09
30 days ago $0.07$0.09
7 days ago $0.07$0.09
Now −$0.50−$0.35

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.12 −$0.28 −333.3%
Mar 2026 −$0.18 −$0.19 −5.6%
Dec 2025 −$0.06 −$0.50 −733.3%
Sept 2025 $0.04 −$0.41 −1125.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold00%
Sell1100%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Petmed Express Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.5%
of tradable shares
Days to cover
6.25
at average volume
Short interest, 1 month
+57%
to October 15, 2026
Held by institutions
37%
of shares
Held by insiders
17.8%
of shares
Employees
189
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −53.3%

$2.57 on October 31, 2025 to $1.20

ThenNowEffect
Revenue (last 12 months) $212m $169m −20.3%
P/S multiple 0.2x 0.2x −39.7%
Share count 21m 21m −2.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −83.4%

$7.21 on November 3, 2023 to $1.20

ThenNowEffect
Revenue (last 12 months) $256m $169m −34.1%
P/S multiple 0.6x 0.2x −73.8%
Share count 20m 21m −3.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PETS−18%−26%−55%−36%−34%−63%
Industry peers (median)−1%−27%+8%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PETS33%42%33%42%25%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PETS−49%−39%−67%−61%−71%−68%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 97% from January 27, 2021 to October 19, 2026. Getting back needed a 3769% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.15 – $3.90
From 52-week high
−69.2%
vs 50-day average
−18.5%
vs 200-day average
−42.9%
Volatility (1 year)
96%
Beta vs S&P 500
1.37

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±12.6%
After a week
3 up, 9 down
typical move ±15.2%
After a month
3 up, 9 down
typical move ±14.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −9.0% +0.5% −12.4% −16.9%
June 2, 2026 −18.0% −0.6% −21.2% −8.8%
November 13, 2025 −31.0% −1.7% −44.5% −1.0%
October 14, 2025 +3.2% +0.3% +6.4% +16.5%
June 16, 2025 −2.2% +0.1% −8.1% −12.6%
February 10, 2025 −14.8% +0.8% −15.8% −22.7%
November 6, 2024 +34.5% +3.3% +23.9% +35.0%
August 6, 2024 −11.0% +0.2% −10.1% −4.5%
June 11, 2024 −0.7% +1.1% +2.9% −6.7%
April 15, 2024 +0.2% −1.4% −2.6% +16.3%
February 8, 2024 +0.7% +0.6% −10.4% −13.5%
October 30, 2023 −26.4% +1.8% −24.1% −22.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Petmed Express Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Petmed Express Inc
$150M $200M $250M $300M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $262.4M Revenue (TTM), FY24 Q3: $268.8M Revenue (TTM), FY24 Q4: $274.1M Revenue (TTM), FY25 Q1: $264.4M Revenue (TTM), FY25 Q2: $253M Revenue (TTM), FY25 Q3: $241.3M Revenue (TTM), FY25 Q4: $227M Revenue (TTM), FY26 Q1: $211.9M Revenue (TTM), FY26 Q2: $198.3M Revenue (TTM), FY26 Q3: $187M Revenue (TTM), FY26 Q4: $179M Revenue (TTM), FY27 Q1: $168.9M $168.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $262.4M
FY24 Q3 $268.8M
FY24 Q4 $274.1M
FY25 Q1 $264.4M
FY25 Q2 $253M
FY25 Q3 $241.3M
FY25 Q4 $227M
FY26 Q1 $211.9M
FY26 Q2 $198.3M
FY26 Q3 $187M
FY26 Q4 $179M
FY27 Q1 $168.9M
Revenue growth, TTM YoY Petmed Express Inc
-30% -20% -10% 0% 10% 20% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: 2.1% Revenue growth, TTM YoY, FY24 Q3: 6.0% Revenue growth, TTM YoY, FY24 Q4: 10.7% Revenue growth, TTM YoY, FY25 Q1: 3.2% Revenue growth, TTM YoY, FY25 Q2: -3.6% Revenue growth, TTM YoY, FY25 Q3: -10.3% Revenue growth, TTM YoY, FY25 Q4: -17.2% Revenue growth, TTM YoY, FY26 Q1: -19.8% Revenue growth, TTM YoY, FY26 Q2: -21.6% Revenue growth, TTM YoY, FY26 Q3: -22.5% Revenue growth, TTM YoY, FY26 Q4: -21.1% Revenue growth, TTM YoY, FY27 Q1: -20.3% -20.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 2.1%
FY24 Q3 6.0%
FY24 Q4 10.7%
FY25 Q1 3.2%
FY25 Q2 -3.6%
FY25 Q3 -10.3%
FY25 Q4 -17.2%
FY26 Q1 -19.8%
FY26 Q2 -21.6%
FY26 Q3 -22.5%
FY26 Q4 -21.1%
FY27 Q1 -20.3%
Operating margin (TTM) Petmed Express Inc
-40% -30% -20% -10% 0% 10% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -0.9% Operating margin (TTM), FY24 Q3: -1.7% Operating margin (TTM), FY24 Q4: -3.0% Operating margin (TTM), FY25 Q1: -0.6% Operating margin (TTM), FY25 Q2: -0.8% Operating margin (TTM), FY25 Q3: 0.3% Operating margin (TTM), FY25 Q4: -0.7% Operating margin (TTM), FY26 Q1: -18.9% Operating margin (TTM), FY26 Q2: -24.7% Operating margin (TTM), FY26 Q3: -31.6% Operating margin (TTM), FY26 Q4: -32.8% Operating margin (TTM), FY27 Q1: -18.2% -18.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -0.9%
FY24 Q3 -1.7%
FY24 Q4 -3.0%
FY25 Q1 -0.6%
FY25 Q2 -0.8%
FY25 Q3 0.3%
FY25 Q4 -0.7%
FY26 Q1 -18.9%
FY26 Q2 -24.7%
FY26 Q3 -31.6%
FY26 Q4 -32.8%
FY27 Q1 -18.2%
FCF margin (TTM) Petmed Express Inc
-20% -10% 0% 10% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: 6.6% FCF margin (TTM), FY24 Q3: 0.6% FCF margin (TTM), FY24 Q4: -0.1% FCF margin (TTM), FY25 Q1: -3.3% FCF margin (TTM), FY25 Q2: -0.4% FCF margin (TTM), FY25 Q3: 0.4% FCF margin (TTM), FY25 Q4: -0.2% FCF margin (TTM), FY26 Q1: -2.2% FCF margin (TTM), FY26 Q2: -7.9% FCF margin (TTM), FY26 Q3: -12.3% FCF margin (TTM), FY26 Q4: -18.4% FCF margin (TTM), FY27 Q1: -16.4% -16.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 6.6%
FY24 Q3 0.6%
FY24 Q4 -0.1%
FY25 Q1 -3.3%
FY25 Q2 -0.4%
FY25 Q3 0.4%
FY25 Q4 -0.2%
FY26 Q1 -2.2%
FY26 Q2 -7.9%
FY26 Q3 -12.3%
FY26 Q4 -18.4%
FY27 Q1 -16.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Mar 2010 2011 Mar 2011 2012 Mar 2012 2013 Mar 2013 2014 Mar 2014 2015 Mar 2015 2016 Mar 2016 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026 LTM Jun 2026
Income
Revenue 238 232 238 228 233 229 235 249 274 283 284 304 272 248 274 227 179 169
Gross profit 92 84 80 77 78 76 76 79 98 95 81 84 77 77 85 69 50 47
EBITDA — — 27 28 29 28 33 39 54 48 33 33 27 10 −1 6 −49 −22
Operating income 41 33 26 27 28 28 32 37 52 46 31 31 24 6 −8 −2 −59 −31
Net income 26 21 17 17 18 17 21 24 37 38 26 24 19 5 −7 −6 −57 −29
Diluted EPS $1.14 $0.92 $0.80 $0.86 $0.90 $0.87 $1.02 $1.17 $1.82 $1.84 $1.29 $1.19 $0.92 $0.25 −$0.37 −$0.30 −$2.74 −$1.38
Growth (year on year)
Revenue — −2.8% +2.9% −4.4% +2.4% −1.7% +2.3% +6.2% +9.9% +3.5% +0.2% +6.8% −10.3% −9.1% +10.7% −17.2% −21.1% −20.3%
EBITDA — — — +2.4% +3.5% −2.8% +17.3% +17.2% +39.7% −10.8% −31.3% −0.8% −18.0% −64.5% −111.5% — −994.6% —
Operating income — −18.5% −21.2% +3.8% +4.5% −2.1% +17.3% +15.7% +39.1% −11.4% −32.9% −1.4% −20.4% −75.1% −234.9% — — —
Net income — −19.7% −20.2% +3.0% +4.7% −2.9% +17.8% +15.8% +56.5% +1.2% −31.5% −7.5% −21.8% −72.5% −245.2% — — —
Diluted EPS — −19.3% −13.0% +7.5% +4.7% −3.3% +17.2% +14.7% +55.6% +1.1% −29.9% −7.8% −22.7% −72.8% −248.0% — — —
Margins
Gross margin 38.6% 36.2% 33.6% 33.9% 33.3% 33.2% 32.5% 31.8% 35.7% 33.6% 28.6% 27.8% 28.3% 30.9% 30.9% 30.5% 28.1% 27.9%
EBITDA margin — — 11.5% 12.3% 12.5% 12.3% 14.1% 15.6% 19.8% 17.1% 11.7% 10.9% 9.9% 3.9% −0.4% 2.4% −27.5% −12.7%
Operating margin 17.0% 14.3% 10.9% 11.9% 12.1% 12.0% 13.8% 15.0% 19.0% 16.3% 10.9% 10.1% 8.9% 2.4% −3.0% −0.7% −32.8% −18.2%
Net margin 10.9% 9.0% 7.0% 7.5% 7.7% 7.6% 8.8% 9.6% 13.6% 13.3% 9.1% 7.9% 6.9% 2.1% −2.7% −2.8% −32.0% −17.3%
Free-cash-flow margin 11.2% 12.7% 8.3% 5.6% 5.8% 13.6% 0.4% 14.7% 13.4% 15.7% 12.9% 12.4% 6.2% 9.1% −0.1% −0.2% −18.4% −16.4%
Cash flow
Cash from operations 28 30 20 13 14 32 21 47 37 45 39 40 18 28 4 5 −28 −24
Capital spending 1 1 1 1 0 1 20 11 1 1 2 2 2 5 5 5 5 4
Free cash flow 27 29 20 13 13 31 1 37 37 45 37 38 17 23 −0 −0 −33 −28
Stock-based pay 2 2 2 2 1 1 2 2 3 3 3 3 5 7 7 −7 1 1
Free cash flow after stock pay 25 27 17 11 12 30 −1 35 34 41 34 34 12 16 −7 6 −34 −29
Balance sheet
Cash 53 50 47 18 18 36 38 59 78 101 104 119 111 104 55 55 21 13
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −53 −50 −47 −18 −18 −36 −38 −59 −78 −101 −104 −119 −111 −104 −55 −55 −21 −13
Diluted shares 23m 23m 21m 20m 20m 20m 20m 20m 20m 20m 20m 20m 20m 20m 20m 21m 21m 21m
Returned to shareholders
Dividends 7 11 11 32 13 14 15 16 17 22 22 23 24 25 12 0 0 0
Buybacks — 12 24 4 — — — — — 0 11 0 0 — — — — —
Total returned 7 23 35 36 13 14 15 16 17 22 33 23 24 25 12 0 0 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 2 checks passed · June 30, 2026
What it owns · $64m
Short-term assets $28mLonger-term assets $36m
What it owes, and who funded it · $64m
Short-term liabilities $41mLonger-term liabilities $0mShareholders' equity $23m
  • Short-term assets cover short-term liabilities $28m of assets due within a year against $41m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $28m short-term assets against $175,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Petmed Express Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$20,000
Diluted share count
+2.9%
year over year
Total shareholder yield
0.1%
dividends 0.1% + buybacks 0.0% of market value
Days sales outstanding
4 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated PETS SBC AIRS NRC RDGT DLHC Median
Revenue, last 12 months $169m $175m $151m $140m $132m $254m $1.2bn
Revenue growth, last 12 months −20.3% −6.9% −8.7% −0.2% 10.2% −29.5% 7.3%
Revenue growth, 3-year average −13.0% — −5.9% −1.9% — −9.5% 11.3%
Revenue growth, latest quarter −19.9% 13.4% −2.5% 4.0% — −46.9% 8.5%
Gross margin 27.9% 71.9% — — 3.6% 24.3% 27.9%
Operating margin −18.2% 37.3% −8.4% 10.5% −1.4% −0.1% 2.3%
Operating margin, 3-year average −12.6% 37.3% −3.0% 19.1% — 3.5% 2.3%
Net margin −17.3% 28.0% −7.8% 4.0% −0.9% −8.5% 1.2%
Cash from operations / revenue −14.1% 35.9% 0.8% 21.1% −1.1% 5.5% 6.1%
Free-cash-flow margin −16.4% 35.3% 0.5% 15.5% −1.1% 5.5% 5.1%
Free-cash-flow margin, 3-year average −7.3% — 0.6% 12.5% — 6.6% 3.6%
Stock pay / revenue 0.6% — 0.8% 8.4% 8.6% 0.5% 1.1%
Change in share count 2.9% 1.4% 13.3% −5.2% 96.6% 2.2% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -20.3% 7.3% 38 of 41
Change in growth rate Growth +0.8pp +1.1pp 22 of 41
Gross margin Profitability 27.9% 29.0% 15 of 27
Operating margin Profitability -18.2% 2.6% 34 of 40
Net margin Profitability -17.3% 1.2% 34 of 41
Free-cash-flow margin Cash generation -16.4% 5.1% 36 of 40
Stock pay as % of revenue Cash generation 0.6% 0.9% 7 of 35
Change in share count Balance sheet 2.9% 0.4% 29 of 39
Days sales outstanding Balance sheet 4 days 39 days 1 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$8.9M
Institutions reporting
49
Shares held vs prior quarter
▼ 22.5%
Positions opened / closed
10 / 9

Top buyers and sellers, Q2 2026: 19 institutions bought and 27 sold ; the biggest buyer was Tudor Investment Corp Et Al (+81K shares) and the biggest seller Hotchkis & Wiley Capital Management LLC (−515K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Renaissance Technologies LLC $2.2M 1.1M 24.3% ▼ 4.6%
Vanguard Capital Management LLC $1.6M 827K 17.8% ▼ 0.5%
Blackrock, Inc. $1.1M 568K 12.2% ▲ 3.0%
Federated Hermes, Inc. $407,367 212K 4.6% ▼ 68.2%
Geode Capital Management, LLC $391,947 204K 4.4% ▼ 7.9%
Steel Partners Holdings L.P. $371,835 194K 4.2% 0.0%
UBS Group AG $265,594 138K 3.0% ▼ 40.8%
Price T Rowe Associates Inc $250,000 130K 2.8% ▲ 8.2%
Bridgeway Capital Management, LLC $232,412 121K 2.6% ▼ 8.8%
Rangeley Capital, LLC $232,320 121K 2.6% ▲ 10.8%
Vanguard Fiduciary Trust Co $212,124 110K 2.4% ▲ 0.7%
State Street Corp $201,932 105K 2.3% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Petmed Express Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $43,750 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $43,750 net buying
Insider Date Trade Shares Price Value
Matz Zyman Stephannie 10% owner June 8, 2026 Buy 25,000 $1.75 $43,750

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • June 2, 2026
  • November 13, 2025
  • October 14, 2025
  • June 16, 2025
  • February 10, 2025

Recent SEC filings

Data status

When each part of this page on Petmed Express Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Petmed Express Inc in brief

What does Petmed Express Inc do?
Petmed Express Inc is a US-listed company in the health care services industry. Its financial year ends in March.
What is Petmed Express Inc's stock ticker?
Petmed Express Inc trades under the ticker PETS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Petmed Express Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Petmed Express Inc reported revenue of $169M, 20.3% lower than a year earlier, according to its SEC filings.
What is Petmed Express Inc's free cash flow?
Petmed Express Inc's free-cash-flow margin is -16.4% of revenue over the trailing twelve months, ranking 36 of the 40 health care services companies we cover.
Who are Petmed Express Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Renaissance Technologies LLC, Vanguard Capital Management LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Petmed Express Inc's market cap?
On November 2, 2026, Petmed Express Inc's market capitalisation was about $25.4M and net debt of -$13.1M. Market figures come from third-party market data and may be delayed.
Does Petmed Express Inc pay a dividend?
Yes: Petmed Express Inc paid $20,000 in dividends over the trailing twelve months, a dividend yield of 0.08%.
Who are Petmed Express Inc's competitors?
In our Health Care Services peer group, the companies closest to Petmed Express Inc are SBC Medical Group Holdings Inc, Airsculpt Technologies, Inc., NRC Health, Ridgetech Inc. and DLH Holdings Corp. The side-by-side comparison below sets their revenue, margins and growth against Petmed Express Inc's.
Are insiders buying or selling Petmed Express Inc stock?
Over the last 12 months, Petmed Express Inc's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Petmed Express Inc's next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Petmed Express Inc announces its own schedule.